ZA200601096B - Omega-3 fatty acids for the treatment of canine ostheoarthritis - Google Patents
Omega-3 fatty acids for the treatment of canine ostheoarthritis Download PDFInfo
- Publication number
- ZA200601096B ZA200601096B ZA200601096A ZA200601096A ZA200601096B ZA 200601096 B ZA200601096 B ZA 200601096B ZA 200601096 A ZA200601096 A ZA 200601096A ZA 200601096 A ZA200601096 A ZA 200601096A ZA 200601096 B ZA200601096 B ZA 200601096B
- Authority
- ZA
- South Africa
- Prior art keywords
- epa
- composition
- dog
- substance
- osteoarthritis
- Prior art date
Links
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 44
- 229940012843 omega-3 fatty acid Drugs 0.000 title claims abstract description 19
- 238000011282 treatment Methods 0.000 title claims description 17
- 239000006014 omega-3 oil Substances 0.000 title claims description 14
- 241000282465 Canis Species 0.000 title description 22
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 230000003349 osteoarthritic effect Effects 0.000 claims abstract description 24
- 230000008407 joint function Effects 0.000 claims abstract description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 32
- 229930195729 fatty acid Natural products 0.000 claims description 32
- 239000000194 fatty acid Substances 0.000 claims description 32
- 230000037396 body weight Effects 0.000 claims description 28
- 235000005911 diet Nutrition 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 230000037213 diet Effects 0.000 claims description 14
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 11
- 239000013589 supplement Substances 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 21
- 238000004519 manufacturing process Methods 0.000 claims 2
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 87
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 87
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 87
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 87
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 72
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 19
- 102000004140 Oncostatin M Human genes 0.000 description 15
- 108090000630 Oncostatin M Proteins 0.000 description 15
- 230000008859 change Effects 0.000 description 15
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 14
- 238000010348 incorporation Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 12
- 230000000378 dietary effect Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 210000003414 extremity Anatomy 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- 206010017577 Gait disturbance Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000009194 climbing Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 230000009191 jumping Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 235000021195 test diet Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 description 2
- 108091005664 ADAMTS4 Proteins 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 108010003059 aggrecanase Proteins 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 230000003050 macronutrient Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 108091005663 ADAMTS5 Proteins 0.000 description 1
- 102000051389 ADAMTS5 Human genes 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000273930 Brevoortia tyrannus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000512294 Thais Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical group 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000021373 diet component Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- -1 g=lucose Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000004722 stifle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63883203A | 2003-08-11 | 2003-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601096B true ZA200601096B (en) | 2007-04-25 |
Family
ID=34216315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601096A ZA200601096B (en) | 2003-08-11 | 2006-02-07 | Omega-3 fatty acids for the treatment of canine ostheoarthritis |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1656130B1 (ru) |
| JP (2) | JP2007502276A (ru) |
| CN (2) | CN101653436B (ru) |
| AT (1) | ATE402695T1 (ru) |
| AU (1) | AU2004266601B2 (ru) |
| BR (1) | BRPI0413287A (ru) |
| CA (1) | CA2529749C (ru) |
| DE (1) | DE602004015472D1 (ru) |
| DK (1) | DK1656130T3 (ru) |
| ES (1) | ES2310757T3 (ru) |
| MX (1) | MXPA05013757A (ru) |
| RU (1) | RU2422140C2 (ru) |
| WO (1) | WO2005018630A1 (ru) |
| ZA (1) | ZA200601096B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8633246B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Omega-3 fatty acids for osteoarthritis |
| US8633247B2 (en) | 2003-08-11 | 2014-01-21 | Hill's Pet Nutrition, Inc. | Method for decreasing cartilage damage in dogs |
| MXPA06015203A (es) * | 2004-07-01 | 2007-03-27 | Nestec Sa | Formulacion de dieta para osteoartritis canina. |
| JP2009540826A (ja) * | 2006-06-20 | 2009-11-26 | ジェンザイム・コーポレーション | 軟骨細胞増幅のための無血清培地およびその使用 |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP2323638B1 (en) * | 2008-07-18 | 2014-05-07 | Hill's Pet Nutrition, Inc. | Compositions and methods for treating osteoarthritis |
| MX2013007191A (es) * | 2010-12-21 | 2013-07-12 | Nestec Sa | Metodos y composiciones para prevenir y tratar la osteoartritis. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015798A (en) * | 1995-10-10 | 2000-01-18 | Colgate Palmolive Company | Method for reducing the damaging effects of radiation therapy on animal skin and mucosa |
| US5843919A (en) * | 1996-11-25 | 1998-12-01 | Burger; John A. | Composition and method for the treatment of arthritis |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| EG22407A (en) * | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
-
2004
- 2004-08-10 WO PCT/US2004/025759 patent/WO2005018630A1/en active Application Filing
- 2004-08-10 CA CA2529749A patent/CA2529749C/en not_active Expired - Fee Related
- 2004-08-10 RU RU2006107197/15A patent/RU2422140C2/ru not_active IP Right Cessation
- 2004-08-10 CN CN200910173492.3A patent/CN101653436B/zh not_active Expired - Fee Related
- 2004-08-10 ES ES04780570T patent/ES2310757T3/es active Active
- 2004-08-10 JP JP2006523277A patent/JP2007502276A/ja active Pending
- 2004-08-10 DK DK04780570T patent/DK1656130T3/da active
- 2004-08-10 CN CNB2004800232516A patent/CN100558352C/zh not_active Expired - Fee Related
- 2004-08-10 AT AT04780570T patent/ATE402695T1/de not_active IP Right Cessation
- 2004-08-10 MX MXPA05013757A patent/MXPA05013757A/es active IP Right Grant
- 2004-08-10 AU AU2004266601A patent/AU2004266601B2/en not_active Ceased
- 2004-08-10 DE DE602004015472T patent/DE602004015472D1/de active Active
- 2004-08-10 EP EP04780570A patent/EP1656130B1/en not_active Not-in-force
- 2004-08-10 BR BRPI0413287-4A patent/BRPI0413287A/pt not_active Application Discontinuation
-
2006
- 2006-02-07 ZA ZA200601096A patent/ZA200601096B/en unknown
-
2012
- 2012-02-14 JP JP2012029785A patent/JP2012116865A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004266601A1 (en) | 2005-03-03 |
| EP1656130B1 (en) | 2008-07-30 |
| CN101653436A (zh) | 2010-02-24 |
| RU2006107197A (ru) | 2006-06-27 |
| EP1656130A1 (en) | 2006-05-17 |
| CA2529749C (en) | 2012-03-20 |
| CA2529749A1 (en) | 2005-03-03 |
| ES2310757T3 (es) | 2009-01-16 |
| CN101653436B (zh) | 2017-06-09 |
| WO2005018630A1 (en) | 2005-03-03 |
| JP2007502276A (ja) | 2007-02-08 |
| RU2422140C2 (ru) | 2011-06-27 |
| BRPI0413287A (pt) | 2006-10-10 |
| ATE402695T1 (de) | 2008-08-15 |
| DE602004015472D1 (de) | 2008-09-11 |
| MXPA05013757A (es) | 2006-03-08 |
| AU2004266601B2 (en) | 2011-03-24 |
| JP2012116865A (ja) | 2012-06-21 |
| CN1835745A (zh) | 2006-09-20 |
| CN100558352C (zh) | 2009-11-11 |
| DK1656130T3 (da) | 2008-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8629183B2 (en) | Methods for decreasing cartilage damage in dogs | |
| Lascelles et al. | Evaluation of a therapeutic diet for feline degenerative joint disease | |
| EP1771091B1 (en) | Canine osteoarthritis diet formulation | |
| ZA200601096B (en) | Omega-3 fatty acids for the treatment of canine ostheoarthritis | |
| JP2009504663A (ja) | 軟骨疾患状態に使用するための組成物および方法 | |
| US8633246B2 (en) | Omega-3 fatty acids for osteoarthritis | |
| ZA200606419B (en) | Glycine and/or proline for use in cartilage affecting conditions | |
| Packington | Biotin for dairy cows. | |
| Ross | Evaluation of oral n-3 polyunsaturated fatty acid effect on the inflammatory response to a novel experimental model of synovitis in the horse | |
| Upah | Dietary strategies to improve periparturient success of Holstein cows |